Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Vonoprazan Sprinkle Capsules vs Tablet
NCT05366738Phase 1Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan in erosive esophagitis (EE), Helicobacter pylori infection and gastroesophageal reflux disease (GERD) (3 arms), sponsored by Phathom Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration, Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity and 1 more. Started May 2022; status: completed.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)Helicobacter pylori infectiongastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05366738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366738.